The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.

Say goodbye to the classic ClinicalTrials.gov!

The classic ClinicalTrials.gov website will be retired on June 25, 2024. Please use the modernized ClinicalTrials.gov. For more information, see ClinicalTrials.gov Modernization.

Key Record Dates

ClinicalTrials.gov Identifier:	NCT02224781
Brief Title:	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

First Submitted :	August 22, 2014
First Submitted that Met QC Criteria :	August 22, 2014
First Posted :	August 25, 2014 (Estimate)

Last Update Submitted that Met QC Criteria :	May 16, 2024
Last Update Posted :	May 20, 2024 (Estimate)

To Top